- Home
- AMZE vs MYNZ Comparison
AMZE vs MYNZ Comparison
Compare AMZE & MYNZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMZE
- MYNZ
- Stock Information
- Founded
- AMZE 2019
- MYNZ 2021
- Country
- AMZE United States
- MYNZ Germany
- Employees
- AMZE N/A
- MYNZ N/A
- Industry
- AMZE Beverages (Production/Distribution)
- MYNZ Biotechnology: Pharmaceutical Preparations
- Sector
- AMZE Consumer Staples
- MYNZ Health Care
- Exchange
- AMZE Nasdaq
- MYNZ Nasdaq
- Market Cap
- AMZE 5.2M
- MYNZ 5.5M
- IPO Year
- AMZE 2021
- MYNZ 2021
- Fundamental
- Price
- AMZE $6.87
- MYNZ $1.98
- Analyst Decision
- AMZE
- MYNZ Buy
- Analyst Count
- AMZE 0
- MYNZ 2
- Target Price
- AMZE N/A
- MYNZ $14.00
- AVG Volume (30 Days)
- AMZE 139.7K
- MYNZ 201.2K
- Earning Date
- AMZE 08-13-2025
- MYNZ 07-22-2025
- Dividend Yield
- AMZE N/A
- MYNZ N/A
- EPS Growth
- AMZE N/A
- MYNZ N/A
- EPS
- AMZE N/A
- MYNZ N/A
- Revenue
- AMZE $254,711.00
- MYNZ $893,991.00
- Revenue This Year
- AMZE N/A
- MYNZ $26.06
- Revenue Next Year
- AMZE N/A
- MYNZ $4.97
- P/E Ratio
- AMZE N/A
- MYNZ N/A
- Revenue Growth
- AMZE N/A
- MYNZ N/A
- 52 Week Low
- AMZE $5.78
- MYNZ $1.34
- 52 Week High
- AMZE $28.72
- MYNZ $19.00
- Technical
- Relative Strength Index (RSI)
- AMZE N/A
- MYNZ 51.21
- Support Level
- AMZE N/A
- MYNZ $1.35
- Resistance Level
- AMZE N/A
- MYNZ $2.15
- Average True Range (ATR)
- AMZE 0.00
- MYNZ 0.14
- MACD
- AMZE 0.00
- MYNZ 0.09
- Stochastic Oscillator
- AMZE 0.00
- MYNZ 55.05
About AMZE Amaze Holdings Inc. Common Stock
Amaze Holdings Inc is engaged in producer of low carb, low calorie, premium wines in the United States. The company offers bold, crisp, and creamy wines that embody health, warmth, and a deeper connection to wellness and an active lifestyle. The company currently sell seven proprietary varietals: Cabernet Sauvignon, Pinot Noir, Chardonnay, Sauvignon Blanc, Rose, Sparkling Rose, and a limited Reserve Napa Cabernet Sauvignon.
About MYNZ Mainz Biomed N.V.
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. The company operates in one operating segment, genetic diagnostic testing.